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ABSTRACT

HeartWareTM
HVADTM System

The HeartWare HVAD System (Medtronic) is a durable implantable left ventricular
assist device that has been implanted in approximately 20,000 patients worldwide
for bridge to transplant and destination therapy indications. In December 2020,
Medtronic issued an Urgent Medical Device Communication informing clinicians
of a critical device malfunction in which the HVAD may experience a delay or failure
to restart after elective or accidental discontinuation of pump operation. Moreover,
evolving retrospective comparative effectiveness studies of patients supported
with the HVAD demonstrated a signiﬁcantly higher risk of stroke and all-cause mortality when compared with a newer generation of a commercially available durable
left ventricular assist device. Considering the totality of this new information on
HVAD performance and the availability of an alternate commercially available device, Medtronic halted the sale and distribution of the HVAD System in June
2021. The decision to remove the HVAD from commercial distribution now requires
the use of the HeartMate 3 left ventricular assist system (Abbott, Inc) if a patient
previously implanted with an HVAD requires a pump exchange. The goal of this
document is to review important differences in the design of the HVAD and HeartMate 3 that are relevant to the medical management of patients supported with
these devices, and to assess the technical aspects of an HVAD-to-HeartMate 3 exchange. This document provides the best available evidence that supports best
practices. (J Thorac Cardiovasc Surg 2022;163:2120-7)

HeartMate 3TM
Left Ventricular Assist System

HVAD to HeartMate 3 Pump Exchange: Best Practices for
Surgical Management

Expert Review of the surgical management of an
HVAD-to-HeartMate 3 LVAD exchange.

CENTRAL MESSAGE

We review best practices for surgical
management of the HVAD-to-HeartMate
3 LVAD exchange procedure.
PERSPECTIVE
In June of 2021, Medtronic halted the sale and distribution of the HVAD system requiring use of the
HeartMate 3 left ventricular assist system in the event
of the need to perform a pump exchange of the
HVAD LVAD. The goal of this Expert Opinion document is to review the relevant surgical management
of an HVAD-to-HeartMate 3 exchange procedure.
See Commentaries on pages 2128 and 2129.
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Abbreviations and Acronyms
BP
¼ blood pressure
LVAD ¼ left ventricular assist device
MAP ¼ mean arterial pressure

Supplemental material is available online.

Video clip is available online.

The HeartWare HVAD System (Medtronic) is a durable left
ventricular assist device (LVAD) approved for bridge to
transplant indication in 2012 and destination therapy
indication in 2019, based on data from the
ADVANCE þ Continued Access Protocol, ENDURANCE,
and ENDURANCE Supplemental clinical studies.1-5 To
date, the device has been implanted in approximately
20,000 patients worldwide and had gained wide adoption,
particularly in clinical scenarios that use a left
anterolateral
thoracotomy
approach
for
device
placement,6 for patients with smaller body size and for
off-label pediatric applications.7 In December 2020, Medtronic issued an Urgent Medical Device Communication informing clinicians of a critical device malfunction in which
the HVAD System may experience a delay or failure to
restart after elective or accidental discontinuation of pump
operation.8 In addition, mounting evidence from retrospective comparative effectiveness studies demonstrated a
significantly higher risk of stroke and all-cause mortality
in HVAD recipients when compared with those receiving
a newer generation of a commercially available durable
LVAD, the HeartMate 3 left ventricular assist system (Abbott, Inc).9-13 In a recent report, the HVAD was associated
with a higher incidence of major neurologic adverse
events in the late constant hazard phase (hazard ratio,
5.71)13 and higher risk of risk of mortality (hazard ratio,
3.20) compared with the HeartMate 3 device.9 Considering
the totality of new information on HVAD performance,
Medtronic halted its sale and distribution in June 2021.
Understandably, numerous concerns and questions have
arisen from clinicians and patients. The most pressing question is how to treat the patients who remain supported with
an HVAD. In particular, 2 options have been advanced: (1)
continue ongoing support with the HVAD, only changing to
a HeartMate 3 “for cause” (ie, pump malfunction or infection); or (2) electively perform an HVAD-to-HeartMate 3
exchange to reduce the potential risk of patient harm that
may occur from a device malfunction related to the “failure

to restart” mode of device failure. Current recommendations from Medtronic support the former strategy. Recent
analyses from The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory
Support registry has similarly supported a “for cause”
approach because continued support on a normally functioning HVAD was associated with less risk than that associated with exchange to a HeartMate 3.14 Furthermore, the
early risk of exchange from an HVAD-to-HeartMate 3 was
similar to that of exchange from an HVAD-to-HVAD, suggesting that patients were not disadvantaged by requiring an
exchange to the HeartMate 3.14
The decision to remove the HVAD from commercial distribution now requires surgeons to use the HeartMate 3 as the
only commercially available device for primary implantation
as well as for exchanging a previously implanted HVAD
(Figures 1 and 2). The goal of this document is to (1) highlight
differences in the design of the HVAD and HeartMate 3 that
are relevant to patient management; and (2) review the surgical management of an HVAD-to-HeartMate 3 exchange. This
document provides the best available evidence and consensus
opinion that support best practices.

MATERIALS AND METHODS
Differences in Device Design and Implications for
Medical Management
Both pumps are continuous-flow LVADs with centrifugal flow design.15,16
The HVAD uses a hybrid engineering design to levitate the internal impeller
with passive magnetic levitation and a hydrodynamic bearing. It incorporates
an optional proprietary pump speed management algorithm, termed the “Lavare Cycle,”17 that is designed to reduce pump and ventricular blood stasis and
improve washout. The HeartMate 3 is designed with complete magnetic levitation of the internal impeller that permits greater distances between the motor
housing and the impeller compared with the gaps that can be achieved with a
hydrodynamic bearing. Its pump operation includes an obligatory change in
pump speed that achieves a reduction in flow stagnation in the pump.18 Recent
data have suggested that the 2 pumps significantly differ in the rates of
hemocompatibility-related adverse events, particularly with respect to
stroke.9-13 Whether these dissimilarities are related to the differences in
pump design or their dynamic pump speed modulation algorithms remains
unknown.
Additional features of the HVAD include a real-time display of pump
waveforms on the HeartWare monitor that depict the variability of blood
flow through the pump and the ongoing collection of pump parameters
and performance data in the Controller logfiles. Information gleaned
from logfiles, when used in combination with clinical data and assessment,
provides critical information on pump performance to support clinical decision making.19 The HeartMate 3 uses the HeartMate Touch Communication System that provides clinicians with the ability to wirelessly monitor
the HeartMate 3 system, program system parameters such as pump speed,
assess and track alarm conditions, and view and save performance data.
The Touch Communication System provides data on pump speed, pump
power, pump flow, and pulsatility index.

Patient Management
It is important to note that anticoagulation, antiplatelet, and blood pressure (BP) management recommendations for the HVAD System have not
been altered as a result of the HVAD device recall.
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used in the HeartMate 3 may cause inaccuracies in determination of
MAP, causing clinicians to overestimate actual MAP27 (Table 1).

Surgical Considerations for Left Ventricular Assist
Device Pump Exchange

ADULT

HVAD to HeartMate 3 Pump Exchange: Best Practices for
Surgical Management
FIGURE 1. With the removal of the HeartWare HVAD System (Medtronic) from commercial distribution, the HeartMate 3 (Abbott, Inc) left
ventricular assist system is now the only commercially available durable
left ventricular assist device device to exchange for an HVAD in the event
of a need to exchange an HVAD device.

Anticoagulation and Antiplatelet Management
Antithrombotic recommendations for the HVAD are based on clinical experience in the ADVANCE þ Continued Access Protocol,1,3
ENDURANCE,4 and ENDURANCE Supplemental clinical studies.5
Recommended antithrombotic therapy included warfarin anticoagulation
targeted to an international normalized ratio of 2.0 to 3.0 as well as antiplatelet therapy with aspirin at more than 81 mg daily. Initial aspirin
dosing of 81 mg was associated with an increased risk of pump thrombosis and stroke.20,21 In ENDURANCE, 29.7% of patients experienced
a stroke with the HVAD device compared with 12.1% of patients
receiving the comparator device, the HeartMate II (Abbott Labs).4 In
the ENDURANCE Supplemental clinical study, 14.7% of patients experienced a stroke with the HVAD device compared with 12.1% of patients
with the HeartMate II device.5
Antithrombotic recommendations for the HeartMate 3 are based on the
clinical experience from the MOMENTUM 3 and HeartMate 3 Conformite
Europeenne Mark clinical studies.22-25 It calls for warfarin anticoagulation
with an international normalized ratio targeted to 2.0 to 3.0 and antiplatelet
therapy with aspirin 81 mg daily. In the MOMENTUM 3 clinical study,
9.9% of patients receiving the HeartMate 3 experienced a stroke
compared with 19.4% receiving the HeartMate II.22 The safety of discontinuing aspirin therapy is currently being evaluated in a multicenter, prospective, randomized, double-blinded clinical trial.23

Blood Pressure Management
BP management is important for both HVAD and HeartMate 3 devices
because continuous-flow devices are afterload sensitive and designed to
optimally perform within a narrow range of BP. Data from the ENDURANCE Supplemental clinical study demonstrated that an enhanced BP protocol significantly reduced mean arterial pressure (MAP) and reduced the
overall stroke rate by 24.2%, with a 50% reduction in hemorrhagic strokes
compared with the original ENDURANCE clinical study in which said protocol was absent.4,5 Current recommendations for BP management for
HVAD recipients include a target MAP less than 85 mm Hg if the patient
has a palpable pulse or less than 90 mm Hg if the patient does not have a
palpable pulse.5,26 A manual cuff and Doppler is the preferred method
for measuring BP.
Conversely, BP management for patients supported by the HeartMate 3
is less well defined. Patients supported on the HeartMate 3 should be maintained with a MAP between 80 and 90 mm Hg unless symptoms of lightheadedness, poor organ perfusion, or other symptoms due to low
pressure supervene, thereby mandating a higher MAP goal. The risk of
hemorrhagic stroke with higher BP goals has not been definitively established as with the HVAD. It is thought that the artificial pulse algorithm
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The global risk associated with LVAD exchange is often related to the
preoperative status of the patient and is also driven by the reasons for the
exchange procedure. A recent systematic review estimated the risk of 30day mortality for pump exchange in the setting of changing devices was
approximately 10% but varied by pump type.28 In addition to pump failure,
comorbidities may include right ventricular failure, hepatic or renal
dysfunction, a history of prior stroke, and ongoing hemolysis, coagulopathy, and platelet dysfunction. All these comorbidities should be considered when deciding on the operative method of exchange. Preoperative
medical management should include (1) discontinuation of long-acting
agents that may suppress the sympathetic nervous system (eg, betablockers, angiotensin receptor neprilysin inhibitor/angiotensin-converting
enzyme inhibitor) to reduce risk of vasoplegia; (2) optimization of right
ventricular function with inotropes, diuretics, or temporary mechanical
support; and (3) optimization of hemostatic function.
First, the appropriate position and angle of the HVAD inflow cannula
must be determined using transesophageal echocardiography or crosssectional contrast study to assess inflow cannula position within the left
ventricular chamber. If malposition of the inflow cannula is present, all
components of the HVAD sewing ring should be removed and the new
HeartMate 3 sewing ring should be attached to the apex. The inflow cannula position of the HeartMate 3 pump can then be optimized with transesophageal echocardiography guidance and traction sutures placed from
the pump to the chest wall or adjusting the length of the outflow graft.
Generous dissection to free adhesions of the heart may be necessary to
permit apical traction to optimize inflow cannula alignment. Extending
the pericardial incision, creating a small preperitoneal space at the left ventricular apex, or opening the left pleura may aid in accommodating the
larger HeartMate 3 pump housing to ensure proper inflow cannula
alignment.

HVAD-to-HeartMate 3 Device Exchange
There are several important technical aspects of the exchange procedure
to consider (Figure 3; Figures E1-E3; Video 1). First is the difference in size
and design of the apical connector/sewing ring between the 2 systems. Second is the discrepancy of the outflow graft diameter between the 2 systems.
Third is the surgical approach for device exchange: sternotomy versus anterolateral thoracotomy. For surgeons with appropriate experience in alternative approaches, an anterolateral thoracotomy approach can be used to
prevent injury to cardiac structures or damage to the outflow graft if
adherent to the posterior sternal table.
Apical sewing ring/connectors. The apical sewing ring of the
HVAD differs significantly from that of the HeartMate 3 (Figures E4 and
E5). The diameter, including the sewing cuff of the HVAD sewing ring,
measures 43 mm in size. The inflow cannula of the HVAD measures
25 mm from the “O” ring to cannula tip and 32.3 mm from pump housing
to cannula tip with a 21-mm outer diameter. The HVAD pump is fabricated
of smooth titanium with sintering halfway up and contains a silicone O-ring
to ensure a seal with the sewing ring. The HVAD inflow cannula has a larger
diameter compared with the inflow cannula of the HeartMate 3.16 The
HVAD sewing ring is constructed of titanium and Dacron polyester and secures the pump inflow cannula in position with the aid of a torque wrench.
The inner portion of the metallic sewing ring is a C-clamp that can be
adjusted by turning a screw inside the clamp to secure the base of pump’s
inflow cannula for optimal placement of the inflow cannula.
The HeartMate 3 device has 2 choices for apical connectors: a larger
size sewing ring with metal housing to maintain a flat geometry of the
felt sewing cuff and a second, smaller design in which the metal housing

The Journal of Thoracic and Cardiovascular Surgery c June 2022

Salerno et al

Adult: Mechanical Circulatory Support: Expert Review

Pump Exchange of a HeartWareTM HVAD TM to HeartMate 3TM Left
Ventricular Assist Device
?
Device Exchange Needed

June 3, 2021, Medtronic Inc. Stops
Distribution and Sale of the HeartWareTM
HVADTM System Due to Risk of
Neurological Adverse Events, Mortality
and Potential Failure to Restart.

Best Surgical Practices

• Exchange of the HVAD device
should be performed only “for
cause” e.g., pump malfunction.

ADULT

Clinical Dilemma

• Assessment of the surgical risks
should determine surgical
approach and technique for the
exchange procedure.
• Remove all HVADTM device
components including sewing
ring and outflow graft when
feasible and safe.
HeartWareTM HVADTM
Left Ventricular Assist Device
HeartMate 3TM
Left Ventricular Assist Device

• Alternative approaches are
available including minimallyinvasive techniques.

FIGURE 2. Pump exchange of a HeartWare HVAD to HeartMate 3 LVAD. Exchange of the HVAD device should be performed only “for cause,” for
example, pump malfunction. The assessment of the surgical risks of the procedure should determine the surgical approach and technique for the exchange
procedure. Removal of all HVAD device components including sewing ring and outflow graft is the optimal technique when feasible and safe. Alternative
approaches are available, including minimally invasive techniques.
has been removed and the size of the felt sewing ring is reduced in size
(Figure E5). The HeartMate 3 inflow cannula measures 22 mm in length
from the pump housing to cannula tip and 20 mm in external diameter.
The outer diameter of the inflow cannula for the HeartMate 3 is smaller

than that of the HVAD and measures only 20.5 mm (this dimension includes the sintering surface) compared with 20.6 mm for the outside diameter of the HVAD inflow cannula.15,16 Thus, the inlet cannula of the
HeartMate 3 cannot simply be placed through the HVAD metallic sewing

TABLE 1. Medical management: Best practices recommendations
BP management
 BP management goals should be individualized to the patient’s condition. Patients and caregivers should be trained to obtain BP readings and record
values before index hospital discharge and should be provided specific MAP targets to notify their clinician for possible intervention.
 For patients supported with an HVAD without a palpable pulse, a manual cuff and Doppler is the preferred method for measuring BP with a MAP
targeting <90 mm Hg.
 For HVAD patients with a palpable pulse, MAP targets should be <85 mm Hg.
 The target goals for BP management for patients supported with the HeartMate 3 are not as well established as those for the HVAD. Patients supported
on the HeartMate 3 should be maintained with a MAP between 80 and 90 mm Hg unless this BP goal is associated with symptoms of lightheadedness,
poor organ perfusion, or other symptoms due to low pressure in which a higher BP goal should be established. The risk of hemorrhagic stroke with
higher BP goals has not been definitively established as with the HVAD.
Anticoagulation
 Patients supported on the HVAD and the HeartMate 3 should be maintained on warfarin anticoagulation with a target international normalized ratio of
2.0 to 3.0.
Antiplatelet therapy
 Patients supported on the HVAD should be maintained on antiplatelet therapy with aspirin at a dose of >81 mg/d.
 Patients supported on the HeartMate 3 should be maintained on antiplatelet therapy with aspirin 81 mg/d.
Device Management and Monitoring
 For the HVAD, clinicians should continue to monitor waveforms in ambulatory and inpatient settings and use Autologs/HVADLogs to better understand
pump performance and to support clinical decision making, including evaluation of suspected pump thrombus, suction events, and so forth. The
Autologs report provides detailed information and trends regarding pump speed/flow/power, medium and high priority alarms, power source data, and
system setting changes.
 For the HeartMate 3, clinicians should continue to monitor pump parameters on a routine basis to assess changes in pump parameters.
 For both devices, it is important to assess the clinical condition of the patient in addition to assessing pump parameters.
BP, Blood pressure; MAP, mean arterial pressure.
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Photograph demonstrating differences in length of the cannula and
height of the pump housing.

HeartMate 3TM LVAD

HVADTM System

ADULT
A
Diagram providing pump weights and cannula lengths for the
HeartMate 3TM and HVADTM
INFLOW
HeartMate 3TM LVAD
Pump

Inflow

Mass (or weight) = 200 g

Length = 22mm

Volume = 80 mL

INFLOW

HVADTM System
Pump

Inflow

Mass (or weight) = 160 g

Length = 32.3mm

Volume = 50 mL

B
FIGURE 3. Comparison of the pump dimensions and size for the HeartMate 3 and HeartWare HVAD System. A, The differences in length of the cannula
and height of the pump housing. B, The pump weights and cannula lengths for the HeartMate 3 and HVAD. The diameter of the inflow cannula of the HVAD
is approximately 20.6 mm, and the diameter of the HeartMate 3 inflow cannula is 20.5 mm. The length of the sintering along the inflow cannula is approximately 11.7 mm for the HVAD and approximately 22 mm for the HeartMate 3. The photographs are courtesy of Angela Lorts, MD, MBA, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio. LVAD, Left ventricular assist device.
ring and obtain a hemostatic seal and requires deviations from the HeartMate 3 implant technique as developed in the MOMENTUM 3 clinical
study and described in the HeartMate 3 Instructions for Use.29-31
Previous reports have described use of a rubber seal to obtain hemostasis
at the inflow connection29,30 (Figure E6). The long-term consequences of
using an improvised seal are unknown.
Outflow graft. The outflow grafts of the HVAD and HeartMate 3
differ in diameter, measuring 10 mm and 14 mm, respectively
(Figure E7). This difference in outflow graft diameter has important implications in the exchange procedure and recommendations for best practices.
During the exchange procedure, complete removal of the HVAD outflow
graft would eliminate the concern for discrepancy in outflow graft sizes.
Suturing of the HeartMate 3 outflow graft to a remnant of the HVAD
outflow graft will necessitate a significant reduction in outflow graft diameter at the anastomosis or distal to it. This reduction in size would increase
afterload to the HeartMate 332 (Figure E8). The long-term consequences of
this increase in afterload to the HeartMate 3 are unknown and may potentially increase the risk of hemocompatibility-related adverse events or
result in inadequate left ventricular unloading and manifestations of heart
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failure. In vitro studies suggest that suturing the 14-mm outflow graft of the
HeartMate 3 to varying lengths of remnants of the HVAD 10-mm outflow
graft increases afterload to the HeartMate 3.32 Additional data suggest that
this added resistance may be overcome by adjustment of pump speed.32
The unknown clinical consequences of higher rotor speeds on hemocompatibility risks, battery runtime, and pump performance with retention of
an HVAD remnant should be balanced against other procedural
considerations.
Exchange procedure. The technique for exchange that is most
consistent with the HeartMate 3 Instructions for Use31 is to completely
excise the preexisting HVAD sewing ring and replace it with a new apical
connector specific to the HeartMate 3 device (Figure E9). Use of circulatory support with cardiopulmonary bypass or extracorporeal membrane
oxygenation is recommended for the exchange procedure to allow inspection of the left ventricular cavity and to ensure that the pannus and left ventricular thrombus are completely removed (Figure E10). The HeartMate 3
apical connector can then be sewn to the left ventricular apex using a series
of interrupted, pledgetted, horizontal mattress sutures (12 individual sutures) for the standard cuff (Figure E11). Alternatively, 4 pledgetted sutures
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VIDEO 1. The surgical procedure to exchange the HVAD LVAD to the
HeartMate 3 LVAD. The steps and surgical techniques of the operative procedure for exchange of an HVAD to HeartMate 3 are reviewed. Provided by
Dr Diyar Saeed, Department of Cardiac Surgery at the Leipzig Heart Center. Video available at: https://www.jtcvs.org/article/S0022-5223(21)
01738-4/fulltext.
followed by a running polypropylene suture can be used to obtain a secure
attachment of the “mini” apical connector to the left ventricular apex.
In addition to removal of the HVAD sewing ring, complete removal of
the outflow graft with enlargement of the aortotomy to accommodate the
14-mm outflow graft of the HeartMate 3 completely eliminates the discrepancy in outflow graft size mismatch (Figure E12). This technique will prevent a pressure drop across the reduced size HVAD outflow graft and avoid
an increase in afterload to the HeartMate 3. However, other procedural considerations must be weighed, including the additional complexity of having
to clamp the ascending aorta partially or fully. Moreover, the use a left anterolateral thoracotomy approach often requires using a remnant of the
HVAD outflow graft.33,34

Alternative surgical techniques for securing the HeartMate 3 to the left ventricular apex. Other options for securing
the HeartMate 3 to the left ventricular apex have been advanced.29,30,33,34
Each has important potential benefits and limitations. If full sternotomy or
complete replacement of the HVAD sewing ring with the HeartMate 3 apical connector poses unacceptable risk as assessed by the surgical team, the
following modifications can be considered.29,30
A. Implantation of the HeartMate 3 by sewing the HeartMate 3 apical
connector over the existing HVAD sewing ring

The HeartMate 3 sewing ring can be sewn to the left ventricle over the
existing HVAD sewing cuff. This is feasible because the sewing ring of the
HeartMate 3 is larger. This approach reduces surgical time because it obviates the amount of dissection needed to remove the existing HVAD apical
sewing ring. However, hemostasis of this approach must be ensured and
may be more technically difficult to achieve compared with full excision
and replacement of the existing HVAD sewing ring. Moreover, this technique reduces the depth of insertion of the HeartMate 3 inflow cannula
into the left ventricular cavity, a configuration with unknown sequelae
(ie, hemocompatibility-related adverse events). Alternatively, the metal
connector portion of the HVAD sewing ring can be removed while leaving
only the fabric portion of the sewing ring. This technique can reduce operative time and potentially have less effect on the depth of insertion of the
HeartMate 3 inflow cannula.
B. Implantation of the HeartMate 3 using the existing apical sewing ring of
the HVAD system
For the implantation of the HeartMate 3 inflow cannula into the remaining HVAD metallic sewing ring, a sterile rubber seal can be placed around
the inflow cannula of the HeartMate 3 to avoid leakage between the HVAD
metallic sewing ring and the inflow cannula of the HeartMate 329,30,33,34
(Figure E6). The inflow cannula of the new HeartMate 3 can then be placed
into the established HVAD metallic sewing ring, and the screw of the
HVAD sewing ring can be tightened. The advantage of this technique is
the reduction in the time needed to replace the HVAD sewing ring and
extent of apical dissection. However, if a reliable seal is not obtained,
bleeding and potential for pseudoaneurysm formation could occur.

Anterolateral left thoracotomy approach versus sternotomy approach. An anterolateral left thoracotomy approach may offer
several advantages to the redo-sternotomy approach for device exchange.33,34 In view of the larger dimensions of the HeartMate 3, a wider
incision is generally required when using an anterolateral thoracotomy
approach.33 A major limitation of this approach is that a longer remnant
of the HVAD outflow graft is left in place because the graft-to-graft anastomosis is typically performed over the acute margin of the right ventricle
just behind the sternum. As suggested, this could significantly increase
afterload to the HeartMate 3 and necessitate increasing the pump speed
of the HeartMate 3 to accommodate the increase in resistance.32 A preoperative computed tomography angiogram should be obtained to exclude
luminal thrombus or extra-luminal compression or kinking of distal segments of the retained HVAD outflow graft. Alternatively, a right upper anterior thoracotomy, tunneling the HeartMate 3 outflow graft through the right
chest, and anastomosis to the ascending aorta at the site of the previous

TABLE 2. Surgical management: Best practices recommendations
Indication for exchange
 Current data do not support “elective” HVAD-to-HeartMate 3 exchange to reduce the potential risk of adverse events arising from a failure to restart
device malfunction.11 Exchange from an HVAD-to-HeartMate 3 should be performed only “for cause” (ie, device thrombosis or device electrical
failure, or device infection not responsive to medical management).
Technique for exchange
 Under optimal clinical scenarios, an HVAD-to-HeartMate 3 exchange should include removal all components of the HVAD device and the apical sewing
cuff of the HeartMate 3 device is sewn to the apex of the left ventricle. The outflow graft of the HVAD System is completely removed to reduce the
discrepancy in outflow graft diameter between the 2 systems.
 It is both safe and feasible to implant a HeartMate 3 device through an anterolateral thoracotomy approach. However, this technique does not address the
issue of discrepancy in size of the outflow graft between the 2 LVAD systems. An upper right anterior thoracotomy or an upper hemi-sternotomy incision
to tunnel the HeartMate 3 outflow graft through the right chest to anastomose to the ascending aorta may be added to the anterolateral thoracotomy
approach for device exchange to exclude all remaining remnants of the HVAD outflow graft. This technique must be balanced against using a remnant of
the HVAD outflow graft.
 Alternative approaches may be considered, if in the opinion of the surgical team, complete excision of all HVAD components poses a unacceptable
surgical risk.
LVAD, Left ventricular assist device.
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HVAD outflow graft can be considered. This technique, although adding an
additional incision and complexity, can completely exclude all the HVAD
outflow graft. Less desirable alternatives to exclude the HVAD outflow
graft include anastomosis of the HeartMate 3 outflow graft to the descending thoracic aorta or the subclavian artery, although these would require
leaving a blind HVAD outflow graft in place. Data on the safety of these
approaches are not available (Table 2).

ADULT

CONCLUSIONS
This document outlines important differences that exist
in both patient management and techniques for surgical exchange of an HVAD-to-HeartMate 3 exchange. Current data
support the recommendation that patients supported with a
normally functioning HVAD should remain on support and
only undergo exchange “for cause” because the risk of
death due to device exchange likely exceeds the risk of
death remaining on a normally functioning HVAD device.
It is likely that future analyses of data from registries of durable LVAD devices will be performed to continue to
monitor evidence to support any changes to this recommendation. Preferably, patients requiring an HVAD-toHeartMate 3 exchange should undergo removal of all
HVAD system components and replacement with HeartMate 3 components unless, in the opinion of the surgical
team, this approach poses unacceptable risk, in which
case, alternative procedures that reduce the extent of dissection and reduce surgical time can be used.
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HeartWareTM
HVADTM System

ADULT

HeartMate 3TM
Left Ventricular Assist System

FIGURE E1. HeartMate 3 left ventricular assist system and HeartWare
HVAD system. The devices are not shown to scale. The devices are shown
without the apical sewing ring or apical connector and without the outflow
graft or outflow graft bend relief. The external diameter of the inflow cannula for the HeartMate 3 is approximately 20 mm, and the external diameter of the HVAD is approximately 21 mm.
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FIGURE E2. Comparison of pump size and cannula length for the HeartMate 3 and HeartWare HVAD system. A, Photograph demonstrating differences in
length of the cannula and height of the pump housing. B, Diagram providing pump weights and cannula lengths for the HeartMate 3 and HVAD.
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FIGURE E5. Apical sewing cuffs of the HeartMate 3 left ventricular
assist system. A, Smaller apical connector with felt sewing cuff, the
“mini-cuff.” B, Larger apical connector with metal housing to maintain a
flat geometry of the felt sewing ring. The metallic ring of the HeartMate
3 apical connector is approximately 20.5 mm in internal diameter and is
smaller than the internal diameter of the metallic ring of the apical
connector of the HVAD (20.6 mm).

Silicone O-ring
to base of pump
a0.18” (a30 mm)
Diameter of base
a018” (a50 mm)

B

Outflow graft (10 mm)

FIGURE E3. Measurements of the HeartMate 3 and HeartWare HVAD
Pumps. A, Measurements of the HeartMate 3 Pump. B, Measurements of
the HeartWare HVAD Pump. Adopted from Adachi and colleagues.E1
All measurements are approximate and obtained from the Instructions
for Use from each respective device.E2,E3

43 mm

Sewing ring screw

FIGURE E4. Apical sewing cuff of the HeartWare HVAD System. The
apical sewing cuff of the HVAD measures 43 mm in external diameter.
The inner portion of the metallic sewing ring is a C-clamp that can be
adjusted by turning a screw inside the clamp to secure the base of HVAD
inflow cannula for optimal placement of the inflow cannula. The metallic
sewing ring is adjustable and accommodates the 20.6-mm external diameter of the HVAD inflow cannula.

FIGURE E6. Demonstration of a rubber seal to obtain hemostasis of the
connection of the HeartMate 3 device inserted into the apical sewing ring of
the HVAD system. Photograph courtesy of Jan Schmitto, MD, PhD (from
Hanke and colleagues).E4 The technique described requires modification to
the HeartMate 3 device and does not follow HeartMate 3 Instructions for
Use.E3
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Pressure (mmHg)

FIGURE E7. Outflow grafts of the HeartMate 3 and Heart HVAD systems. A, The 10-mm outflow graft of the HeartWare HVAD system. B,
The 14-mm outflow graft of the HeartMate 3 left ventricular assist system.
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FIGURE E8. Head pressure flow (HQ) curves for the HeartWare HVAD System and HeartMate 3 left ventricular assist system. These data represent HQ
curves for HVAD and HeartMate 3 pumps with their respective outflow grafts connected to the pumps. The HQ curves published in the HVAD and HeartMate 3 Instructions for Use represent HQ curves based upon flow from the pumps without outflow grafts attached. The HQ curves above represent flow at
varying pump speeds with the added resistance of the outflow grafts and give approximate pump speeds to achieve similar pump flows with the respective
pumps. Data are unpublished observations provided by Eric Corndorf, Medtronic, Inc, 2021.
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FIGURE E11. The HeartMate 3 apical connector can be sewn to the left
ventricular apex using a series of interrupted, pledgetted, horizontal
mattress sutures (12 individual sutures) for the standard cuff. Photograph
courtesy of Francis D. Pagani, MD, PhD.

FIGURE E9. Intraoperative photograph demonstrating removal of the
HVAD pump and complete excision of the HVAD apical sewing ring
through a redo-sternotomy approach with cardiopulmonary bypass. Photograph courtesy of Francis D. Pagani, MD, PhD.

FIGURE E10. Pannus removed from the left ventricular cavity after inspection and removal of the HVAD pump and apical sewing cuff. Photograph courtesy of Francis D. Pagani, MD, PhD.

FIGURE E12. Complete removal of the HVAD outflow graft and anastomosis of the 14-mm HeartMate 3 outflow graft to the greater curvature of
the ascending aorta. Photograph courtesy of Francis D. Pagani, MD, PhD.
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